CHICAGO (EGMN) - Bone marrow purging with rituximab followed by autologous stem cell transplant and rituximab maintenance significantly increased the 5-year progression-free survival rate for patients with relapsed/refractory follicular lymphoma in the European Group for Blood and Marrow Transplantation Lym-1 trial.In an intention-to-treat analysis of 280 patients at a median follow-up of 6.4 years, the rate among those who were randomized to rituximab (Rituxan, MabThera) purging and maintenance...